Observations on the disposition of probenecid in patients receiving allopurinol.

  title={Observations on the disposition of probenecid in patients receiving allopurinol.},
  author={T. Budya Tjandramaga and Samuel A. Cucinell and Zafar H. Israili and James M. Perel and Peter G. Dayton and Ts'ai-fan Y{\"u} and Alexander B. Gutman},
  volume={8 4},
The effect of allopurinol on the metabolism of pro benecid was evaluated in patients for two reasons: allopurinol was re ported to inhibit drug metabolism, and combined therapy (allopurinol and probenecid) is occasionally employed in the treatment of gout. Metabolism of probenecid was estimated by the determination of probenecid plasma level decay (T½). ln 8 of 14 subjects, a prolongation of T½ was found during concurrent allopurinol treatment. Allopurinol isboth a substrate and an inhibitor of… 
Clinical Pharmacokinetics of Probenecid
There are 2 primary clinical uses for probenecid: as a uricosuric agent in the treatment of chronic gout and as an adjunct to enhance blood levels of antibiotics (such as penicillins and Cephalosporins).
Pharmacokinetic and Pharmacodynamic Interaction between Allopurinol and Probenecid in Healthy Subjects
Coadministration of allopurinol and probenecid to healthy subjects had a greater hypouricaemic effect than either alloporinol or probenacid alone, despite a reduction in plasma oxypurinl concentrations when the drugs were taken concomitantly.
Pharmacokinetic and Pharmacodynamic Interaction Between Allopurinol and Probenecid in Patients with Gout
Coadministration of allopurinol with probenecid had a significantly greater hypouricemic effect than alloporinol alone despite an associated reduction of plasma oxypurinols concentrations.
The influence of allopurinol and size of dose on the metabolism of phenylbutazone in patients with gout
SummaryAdministration of allopurinol 300 mg/day produced minimal changes in the disappearance of phenylbutazone in each of five subjects following single doses (6 mg/kg) in clinical range and caused
The effect of probenecid on the renal tubular excretion of benzylpenicillin.
Extrapolating these results to the clinical situation, the commonly used daily dose of 2 g of probenecid is likely to be close to the maximal effective dose for inhibition of the tubular excretion of benzylpenicillin.
Allopurinol and Other Inhibitors of Urate Synthesis
Inhibition of xanthine oxidase has proven to be a clinically safe and effective method of reducing uric acid formation.
Antirheumatic Drugs: Clinical Pharmacology and Therapeutic Use
Hope for future therapeutic development is highest in rheumatoid arthritis with the second-line agents (e.g. gold, penicillamine), as unravelling their mechanism of action may lead to the design of more effective and less toxic medications.
Prediction of the clinical efficacy of and intolerance to antirheumatic drug therapy
The encouraging results seen initially following the use of 1 g of intravenous methylprednisolone have waned somewhat since the demonstration of equivalent short-term clinical effects using 1 g oral prednisol one and the fact that clinical and immunologic response is transient is transient.
The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
It is demonstrated that the efficacy of standard dose 300 mg of allopurinol is superior to a combined low dose of allo-drugs and benzbromarone in lowering the level of serum uric acid level.